Dr Tahara (National Cancer Center Hospital East, Kashiwa, Japan) talks to ecancertv at ESMO 2014 about the development of a new targeted therapy for the treatment of iodine-refractory thyroid cancer.
Related Videos In Thyroid Cancer
Lori J Wirth, ASCO 2018 – Treatment Approaches and Advances in Thyroid Cancer Research
touchONCOLOGY meets with Lori J Wirth from Harvard Medical School and Massachusetts General Hospital in Boston, MA to discuss important treatment approaches and advances for thyroid cancer, including investigating lenvatinib and major findings of the SELECT trial, and how the clinical development of new therapies such as LOXO-292 and spartalizumab may contribute to treatment paradigms […]
ESMO 2016 Lars Bastholt Interview
Dr Lars Bastholt discusses lenvatinib for the treatment of differentiated thyroid cancer. FILMED AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) ANNUAL MEETING, OCTOBER 2016.
Efficacy/Safety of Lenvatinib for the treatment of pts w/ 131I-refractory thyroid cancer
ASCO 2015: Matthew Taylor, MD discusses efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy.
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!